NEWS​

News & Press Releases

05/29/2026

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Continued HBsAg Declines, Without Rebound, Up to Two Plus Years, After a Single VRON-0200 Dose, From its Phase 1b Study at EASL 2026

02/22/2026

VRON-0200 Induced Broad and Sustained Anti-HBV Immunity in Chronically HBV-Infected Patients

11/09/2025

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b Study at AASLD’s The Liver Meeting® 2025

10/07/2025

Virion Therapeutics Announces Upcoming Clinical Presentation Highlighting VRON-0200 Study Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2025

07/28/2025

Virion Therapeutics Provides Update on its VRON-0200 Clinical Development Program for HBV Functional Cure on World Hepatitis Day 2025

05/07/2025

Virion Therapeutics Reports New Data from Two Clinical Presentations at EASL 2025, including Rapid and Profound Hepatitis B Surface Antigen Declines with the First VRON-0200 Containing Combination Therapy for HBV Functional Cure

03/28/2025

Virion Therapeutics Reports Positive Clinical Data with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at APASL 2025 Global Liver Meeting

01/10/2025

Virion Therapeutics Completes Enrollment of First 2 Cohorts of Phase 1b Chronic Hepatitis B Trial of VRON-0200 For HBV Functional Cure

11/19/2024

Virion Therapeutics Reports First-Ever Clinical Responses with VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure, at AASLD's The Liver Meeting®

09/23/2024

Healey-Driscoll Administration Announces Nearly $20 Million in Life Sciences Funding to Advance Innovation in Research and Development, Data Science, Drug Delivery, and Women’s Health

06/05/2024

Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress

03/27/2024

Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting

10/26/2023

Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection

10/12/2023

Virion Therapeutics and Ocean Biomedical form joint venture supporting multinational, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwide

06/21/2023

Virion Therapeutics Presents VRON-0200 Preclinical Data Showing Direct Correlations Between Intrahepatic CD8+ T cells and Hepatitis B Virus Declines (HBV) at EASL 2023

03/06/2023

Virion Therapeutics Presents Promising Preclinical Cancer Data When Using a Novel Genetically Encoded Checkpoint Modifier-Based Immunotherapy

02/22/2023

Center for Breakthrough Medicines and Virion Therapeutics Announce Strategic Partnership to Manufacture Virion's Proprietary CD8+ T cell-based Clinical Development Programs for Infectious Diseases and Cancers

03/10/2022

Andrew Luber commenting on the thriving life sciences and biotech industry in Philadelphia, USA

11/22/2021

Virion Therapeutics, LLC Announces the Appointment of Sue Currie, Ph.D. as Chief Operating Officer

07/12/2021

Virion Therapeutics, LLC Announces the Appointment of M. Michelle Berrey, M.D., M.P.H. and Williamson Bradford, M.D., Ph.D. to Its Board of Directors

06/25/2021

Virion Therapeutics Presents Data Showing Enhanced and Sustained Virus Declines in Animals upon Immunization with VRON-0200, a Therapeutic Vaccine for Chronic Hepatitis B Virus (HBV) Infections at the International Liver Congress (ILC)

11/17/2020

Virion Therapeutics Wins Prestigious ‘Most Valued Company’ at Keiretsu Forum Investor Capital Expo

10/01/2018

Virion Therapeutics, LLC Announces its Inaugural Board of Directors and Scientific Advisory Board Members

09/16/2018

Virion Therapeutics, LLC Raises $5 Million to Develop Checkpoint Inhibitor Powered Vaccine Therapies for Treatment of Virally Induced Infectious Diseases & Cancers